DNA Methylation-Based Diagnosis and Treatment of Breast Cancer
This article focuses on the relevance of DNA methylation to breast cancer, describing the role of detecting DNA methylation in the early diagnosis, prediction, progression, metastasis, treatment, and prognosis of breast cancer, as well as recent advances. The reversibility of DNA methylation is utilized to target specific methylation aberrant promoters as well as related enzymes, from early prevention to late targeted therapy, to understand the journey of DNA methylation in breast cancer with a more comprehensive perspective. Meanwhile, methylation inhibitors in combination with other therapies have a wide range of prospec...
Source: Current Cancer Drug Targets - March 5, 2024 Category: Cancer & Oncology Authors: Xintong Peng Jingfan Zheng Tianzi Liu Ziwen Zhou Chen Song Danyan Zhang Xinlong Zhang Yan Huang Source Type: research
DNA Methylation-Based Diagnosis and Treatment of Breast Cancer
This article focuses on the relevance of DNA methylation to breast cancer, describing the role of detecting DNA methylation in the early diagnosis, prediction, progression, metastasis, treatment, and prognosis of breast cancer, as well as recent advances. The reversibility of DNA methylation is utilized to target specific methylation aberrant promoters as well as related enzymes, from early prevention to late targeted therapy, to understand the journey of DNA methylation in breast cancer with a more comprehensive perspective. Meanwhile, methylation inhibitors in combination with other therapies have a wide range of prospec...
Source: Current Cancer Drug Targets - March 5, 2024 Category: Cancer & Oncology Authors: Xintong Peng Jingfan Zheng Tianzi Liu Ziwen Zhou Chen Song Danyan Zhang Xinlong Zhang Yan Huang Source Type: research
Bioinformatics and Experimental Study revealed LINC00982/ miR-183-5p/ABCA8 Axis Suppresses LUAD Progression
CONCLUSIONS: Our findings revealed the LINC00982/miR-183-5p/ABCA8 axis as a potential therapeutic target in LUAD.PMID:38419344 | DOI:10.2174/0115680096266700231107071222 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - February 29, 2024 Category: Cancer & Oncology Authors: Defang Ding Jingyu Zhong Yue Xing Yangfan Hu Xiang Ge Weiwu Yao Source Type: research
Bioinformatics and Experimental Study revealed LINC00982/ miR-183-5p/ABCA8 Axis Suppresses LUAD Progression
CONCLUSIONS: Our findings revealed the LINC00982/miR-183-5p/ABCA8 axis as a potential therapeutic target in LUAD.PMID:38419344 | DOI:10.2174/0115680096266700231107071222 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - February 29, 2024 Category: Cancer & Oncology Authors: Defang Ding Jingyu Zhong Yue Xing Yangfan Hu Xiang Ge Weiwu Yao Source Type: research
Bioinformatics and Experimental Study revealed LINC00982/ miR-183-5p/ABCA8 Axis Suppresses LUAD Progression
CONCLUSIONS: Our findings revealed the LINC00982/miR-183-5p/ABCA8 axis as a potential therapeutic target in LUAD.PMID:38419344 | DOI:10.2174/0115680096266700231107071222 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - February 29, 2024 Category: Cancer & Oncology Authors: Defang Ding Jingyu Zhong Yue Xing Yangfan Hu Xiang Ge Weiwu Yao Source Type: research
TBOPP, a DOCK1 Inhibitor, Potentiates Cisplatin Efficacy in Breast Cancer by Regulating Twist-mediated EMT
CONCLUSION: Taken together, these results demonstrate that DOCK1 may function as a potential therapeutic target in BC and that combining cisplatin with TBOPP may provide a promising therapeutic strategy for cisplatin-resistant BC patients.PMID:38415469 | DOI:10.2174/0115680096281231240202073558 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - February 28, 2024 Category: Cancer & Oncology Authors: Xin Chen Zhenbang Zhou Pengting Tang Feiya Du Shuqian Wang Jia Yao Shufen Zhang Jiajing Huang Xuemei Lu Wei Chen Xiaofang Yu Yu Liu Hao Liu Source Type: research
TBOPP, a DOCK1 Inhibitor, Potentiates Cisplatin Efficacy in Breast Cancer by Regulating Twist-mediated EMT
CONCLUSION: Taken together, these results demonstrate that DOCK1 may function as a potential therapeutic target in BC and that combining cisplatin with TBOPP may provide a promising therapeutic strategy for cisplatin-resistant BC patients.PMID:38415469 | DOI:10.2174/0115680096281231240202073558 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - February 28, 2024 Category: Cancer & Oncology Authors: Xin Chen Zhenbang Zhou Pengting Tang Feiya Du Shuqian Wang Jia Yao Shufen Zhang Jiajing Huang Xuemei Lu Wei Chen Xiaofang Yu Yu Liu Hao Liu Source Type: research
The Prognostic Value and Clinical Significance of lncRNA SNHG5 Expression in Patients with Multiple Malignancies: A Bioinformatic and Meta-Analysis
CONCLUSION: These results suggest that lncRNA SNHG5 may serve as an adverse prognostic biomarker in several human cancers. Further investigations are needed to better understand the underlying mechanisms that link lncRNA SNHG5 to multiple malignancies.PMID:38409690 | DOI:10.2174/0115680096282865240111055640 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - February 27, 2024 Category: Cancer & Oncology Authors: Mehran Pashirzad Amirhossein Sahebkar Source Type: research
An Overview of the Dichotomous Role of Microbiota in Cancer Progression and Management
Curr Cancer Drug Targets. 2024 Feb 21. doi: 10.2174/0115680096282503240124104029. Online ahead of print.ABSTRACTIt is a well-known fact that cancer is considered the second leading cause of mortality across the globe. Although the human oral cavity and intestine are the natural habitat of thousands of microbes, dysbiosis results in malignancies, such as oral squamous cell carcinoma and colorectal cancer. Amongst the intestinal microbes, H. pylori is a deadly carcinogen. Also, causative pathogens for the development of pancreatic and colorectal cancer are found in the oral cavity, such as Fusobacterium nucleatum and Porphyr...
Source: Current Cancer Drug Targets - February 27, 2024 Category: Cancer & Oncology Authors: Pooja Jain Sradhanjali Mohapatra Uzma Farooq Nazia Hassan Mohd Aamir Mirza Zeenat Iqbal Source Type: research
Thyroid Metastases from Breast Cancer Case Report and Literature Review
CONCLUSION: Given the unusual clinical indicators, identifying heterochronic thyroid metastases in patients with tumors poses a distinct challenge, requiring clinicians to navigate the follow-up process with heightened sensitivity. The key lies in timely detection and early intervention, factors that can significantly enhance the overall quality of life for patients.PMID:38409692 | DOI:10.2174/0115680096274465240129055950 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - February 27, 2024 Category: Cancer & Oncology Authors: Yumei Guan Qinjun Ma Yiqing Zhang Jiuda Zhao Xinjian Guo Source Type: research
The Prognostic Value and Clinical Significance of lncRNA SNHG5 Expression in Patients with Multiple Malignancies: A Bioinformatic and Meta-Analysis
CONCLUSION: These results suggest that lncRNA SNHG5 may serve as an adverse prognostic biomarker in several human cancers. Further investigations are needed to better understand the underlying mechanisms that link lncRNA SNHG5 to multiple malignancies.PMID:38409690 | DOI:10.2174/0115680096282865240111055640 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - February 27, 2024 Category: Cancer & Oncology Authors: Mehran Pashirzad Amirhossein Sahebkar Source Type: research
An Overview of the Dichotomous Role of Microbiota in Cancer Progression and Management
Curr Cancer Drug Targets. 2024 Feb 21. doi: 10.2174/0115680096282503240124104029. Online ahead of print.ABSTRACTIt is a well-known fact that cancer is considered the second leading cause of mortality across the globe. Although the human oral cavity and intestine are the natural habitat of thousands of microbes, dysbiosis results in malignancies, such as oral squamous cell carcinoma and colorectal cancer. Amongst the intestinal microbes, H. pylori is a deadly carcinogen. Also, causative pathogens for the development of pancreatic and colorectal cancer are found in the oral cavity, such as Fusobacterium nucleatum and Porphyr...
Source: Current Cancer Drug Targets - February 27, 2024 Category: Cancer & Oncology Authors: Pooja Jain Sradhanjali Mohapatra Uzma Farooq Nazia Hassan Mohd Aamir Mirza Zeenat Iqbal Source Type: research
Thyroid Metastases from Breast Cancer Case Report and Literature Review
CONCLUSION: Given the unusual clinical indicators, identifying heterochronic thyroid metastases in patients with tumors poses a distinct challenge, requiring clinicians to navigate the follow-up process with heightened sensitivity. The key lies in timely detection and early intervention, factors that can significantly enhance the overall quality of life for patients.PMID:38409692 | DOI:10.2174/0115680096274465240129055950 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - February 27, 2024 Category: Cancer & Oncology Authors: Yumei Guan Qinjun Ma Yiqing Zhang Jiuda Zhao Xinjian Guo Source Type: research
Insights into the Emerging Therapeutic Targets of Triple-negative Breast Cancer
Curr Cancer Drug Targets. 2024 Feb 21. doi: 10.2174/0115680096280750240123054936. Online ahead of print.ABSTRACTTriple-negative Breast Cancer (TNBC), the most aggressive breast cancer subtype, is characterized by the non-appearance of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Clinically, TNBC is marked by its low survival rate, poor therapeutic outcomes, high aggressiveness, and lack of targeted therapies. Over the past few decades, many clinical trials have been ongoing for targeted therapies in TNBC. Although some classes, such as Poly (ADP Ribose) Polymerase...
Source: Current Cancer Drug Targets - February 22, 2024 Category: Cancer & Oncology Authors: Magham Sai Varshini Praveen Thaggikuppe Krishnamurthy Ramakamma Aishwarya Reddy Ashish Wadhwani V M Chandrashekar Source Type: research
Insights into the Emerging Therapeutic Targets of Triple-negative Breast Cancer
Curr Cancer Drug Targets. 2024 Feb 21. doi: 10.2174/0115680096280750240123054936. Online ahead of print.ABSTRACTTriple-negative Breast Cancer (TNBC), the most aggressive breast cancer subtype, is characterized by the non-appearance of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Clinically, TNBC is marked by its low survival rate, poor therapeutic outcomes, high aggressiveness, and lack of targeted therapies. Over the past few decades, many clinical trials have been ongoing for targeted therapies in TNBC. Although some classes, such as Poly (ADP Ribose) Polymerase...
Source: Current Cancer Drug Targets - February 22, 2024 Category: Cancer & Oncology Authors: Magham Sai Varshini Praveen Thaggikuppe Krishnamurthy Ramakamma Aishwarya Reddy Ashish Wadhwani V M Chandrashekar Source Type: research
